Separate terms with OR to return results that match either term.
 
Clear All

9,186 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status (Ascending)
00069-0315-01 00069-0315 Bevacizumab-bvzr Zirabev 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Jan. 13, 2020 In Use
00069-0342-01 00069-0342 Bevacizumab-bvzr Zirabev 400.0 mg/16mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Jan. 13, 2020 In Use
00069-0324-01 00069-0324 Pegfilgrastim-apgf NYVEPRIA 6.0 mg/.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Dec. 15, 2020 In Use
00093-7766-24 00093-7766 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 10, 2020 In Use
00093-7767-24 00093-7767 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 10, 2020 In Use
00093-7768-24 00093-7768 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 10, 2020 In Use
00703-3216-01 00703-3216 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 25, 2020 In Use
00703-3216-81 00703-3216 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 5, 2020 In Use
00703-3217-01 00703-3217 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 5, 2020 In Use
00703-3213-01 00703-3213 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 7, 2020 In Use
00703-3213-81 00703-3213 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous July 7, 2020 In Use
00703-3218-01 00703-3218 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 5, 2020 In Use
00703-3218-81 00703-3218 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 5, 2020 In Use
00338-0067-01 00338-0067 doxorubicin hydrochloride DOXIL 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 13, 2019 In Use
00338-0063-01 00338-0063 doxorubicin hydrochloride DOXIL 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Aug. 13, 2019 In Use
00069-0688-03 00069-0688 palbociclib Ibrance 125.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
00069-0486-03 00069-0486 Palbociclib Ibrance 100.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 30, 2020 In Use
73150-0200-12 73150-0200 umbralisib UKONIQ 260.2 mg/1 Chemotherapy Enzyme Inhibitor PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 Oral Feb. 5, 2021 In Use
73153-0900-01 73153-0900 Lisocabtagene maraleucel BREYANZI Immunotherapy CAR-T CD19 Feb. 5, 2021 In Use
73462-0101-01 73462-0101 Trilaciclib Cosela 300.0 mg/20mL Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Intravenous Feb. 12, 2021 In Use
00054-0480-13 00054-0480 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Feb. 12, 2021 In Use
00054-0480-14 00054-0480 Everolimus Everolimus 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2020 In Use
00054-0481-13 00054-0481 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Feb. 12, 2021 In Use
00054-0481-14 00054-0481 Everolimus Everolimus 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2020 In Use
00054-0497-13 00054-0497 Everolimus Everolimus 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Feb. 12, 2021 In Use

Found 9,186 results in 5 millisecondsExport these results